CYCLOSPORIN A: may prevent lethal reaction after marrow transplant

InPharma ◽  
1980 ◽  
Vol 227 (1) ◽  
pp. 8-8
Keyword(s):  
Cyclosporin A ◽  
Marrow Transplant ◽  
Lethal Reaction

scholarly journals Impaired erythropoietin production in mice treated with cyclosporin A

Blood ◽  
1991 ◽  
Vol 78 (6) ◽  
pp. 1615-1618 ◽  
Author(s):  
AM Vannucchi ◽  
A Grossi ◽  
A Bosi ◽  
D Rafanelli ◽  
S Guidi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Animal Model ◽  
Cyclosporin A ◽  
Renal Toxicity ◽  
Reference Population ◽  
Marrow Transplant ◽  
Allogeneic Bone ◽  
Kidney Toxicity ◽  
Erythropoietin Production

Abstract Because recent data indicate that erythropoietin (Epo) production is defective in allogeneic bone marrow transplant (BMT) patients, we investigated the role of the immunosuppressant, nephrotoxic, agent cyclosporin A (CsA) on renal Epo production using an animal model. Mice were injected with 1.0 to 40.0 mg/kg/d CsA for 15 days. Thereafter, circulating Epo levels were evaluated in both intact animals and in mice made anemic with phenylhydrazine (PHZ). Serum Epo levels measured in CsA-treated animals were then compared with the predicted levels, which had been calculated in a reference population of normal, either intact or anemic, mice. In CsA-treated, intact animals both hematocrit and serum Epo levels were not significantly different from controls. However, serum Epo levels in CsA-treated, anemic mice were significantly lower than those expected in a control population of untreated, anemic mice with similar degrees of anemia. No significant increase in serum creatinine was recorded even at the highest doses of CsA used, nor were we able to document signs of renal toxicity by histologic examination of the kidneys. Therefore, therapeutical doses of CsA appear to affect the production of Epo under conditions in which the demand of the hormone is increased, as in response to anemia. We suggest that a subclinical kidney toxicity produced by CsA might have a role in the pathogenesis of the impaired Epo production observed in BMT patients, and may contribute to a delayed erythroid engraftment in at least some BMT patients.

SERUM LEVELS OF CYCLOSPORIN A AND NEPHROTOXICITY IN BONE MARROW TRANSPLANT PATIENTS

The Lancet ◽  
1981 ◽  
Vol 318 (8238) ◽  
pp. 145-146 ◽  
Author(s):  
J.M. Hows ◽  
S. Palmer ◽  
S. Want ◽  
C. Dearden ◽  
E.C. Gordon-Smith
Keyword(s):  
Bone Marrow ◽  
Cyclosporin A ◽  
Bone Marrow Transplant ◽  
Serum Levels ◽  
Marrow Transplant ◽  
Transplant Patients

scholarly journals Impaired erythropoietin production in mice treated with cyclosporin A

Blood ◽  
1991 ◽  
Vol 78 (6) ◽  
pp. 1615-1618 ◽  
Author(s):  
AM Vannucchi ◽  
A Grossi ◽  
A Bosi ◽  
D Rafanelli ◽  
S Guidi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Animal Model ◽  
Cyclosporin A ◽  
Renal Toxicity ◽  
Reference Population ◽  
Marrow Transplant ◽  
Allogeneic Bone ◽  
Kidney Toxicity ◽  
Erythropoietin Production

Because recent data indicate that erythropoietin (Epo) production is defective in allogeneic bone marrow transplant (BMT) patients, we investigated the role of the immunosuppressant, nephrotoxic, agent cyclosporin A (CsA) on renal Epo production using an animal model. Mice were injected with 1.0 to 40.0 mg/kg/d CsA for 15 days. Thereafter, circulating Epo levels were evaluated in both intact animals and in mice made anemic with phenylhydrazine (PHZ). Serum Epo levels measured in CsA-treated animals were then compared with the predicted levels, which had been calculated in a reference population of normal, either intact or anemic, mice. In CsA-treated, intact animals both hematocrit and serum Epo levels were not significantly different from controls. However, serum Epo levels in CsA-treated, anemic mice were significantly lower than those expected in a control population of untreated, anemic mice with similar degrees of anemia. No significant increase in serum creatinine was recorded even at the highest doses of CsA used, nor were we able to document signs of renal toxicity by histologic examination of the kidneys. Therefore, therapeutical doses of CsA appear to affect the production of Epo under conditions in which the demand of the hormone is increased, as in response to anemia. We suggest that a subclinical kidney toxicity produced by CsA might have a role in the pathogenesis of the impaired Epo production observed in BMT patients, and may contribute to a delayed erythroid engraftment in at least some BMT patients.

scholarly journals Adsorption and pharmacokinetics of cyclosporin A in relation to mode of infusion in bone marrow transplant patients

2000 ◽  
Vol 25 (6) ◽  
pp. 633-638 ◽  
Author(s):  
N Shibata ◽  
Y Ikuno ◽  
Y Tsubakimoto ◽  
N Hoshino ◽  
T Minouchi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cyclosporin A ◽  
Bone Marrow Transplant ◽  
Marrow Transplant ◽  
Transplant Patients

Lymphoma of host origin in a marrow transplant recipient in remission of acute myeloid leukemia and receiving cyclosporin A

1985 ◽  
Vol 18 (1) ◽  
pp. 73-83 ◽  
Author(s):  
Robert E. Bloom ◽  
James K. Brennan ◽  
John L. Sullivan ◽  
R. S. K. Chiganti ◽  
Robert Dinsmore ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Transplant Recipient ◽  
Cyclosporin A ◽  
Myeloid Leukemia ◽  
Marrow Transplant ◽  
Host Origin ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document